Last checked at 28 Jan 2016 12:51
OptiBiotix Health Plc
(the "Company" or the "Group")
Investor Presentation - Change of venue
OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces a change of venue for the presentation for investors due to take place on Tuesday, 16 February 2016.
Due to popular demand, the event will now be held in the Oriental room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm for a 4.45pm start.
All other details remain the same as stated in the RNS published on 20 January 2016.
To register for the event, please email optibiotix@walbrookpr.com or call the Walbrook PR team below. If you have already registered, you need not take any further action.
OptiBiotix Health plc | www.optibiotix.com |
Stephen O'Hara, Chief Executive | Contact via Walbrook below |
Cairn Financial Advisers LLP | Tel: 020 7148 7900 |
Liam Murray / Avi Robinson | |
Hybridan LLP (Joint Broker) Claire Louise Noyce
| Tel: 020 3764 2341 |
Peterhouse Corporate Finance Ltd (Joint Broker) | Tel: 020 7469 0936 |
Lucy Williams / Duncan Vasey | |
Walbrook PR Ltd | Tel: 020 7933 8780 or optibiotix@walbrookpr.com |
Anna Dunphy | Mob: 07876 741 001 |
Mike Wort | Mob: 07900 608 002 |
About OptiBiotix Health PLC - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.